Piramal Pharma Limited

Piramal Pharma fined ₹1 crore by GPCB for environmental damage at Dahej plant

Piramal Pharma Limited has been imposed an interim environmental damage compensation of ₹1 crore by the Gujarat Pollution Control Board for its Dahej plant. The company is engaging with authorities for a resolution. No material impact on financial or operational activities is reported currently.

Piramal Pharma Partners with Blue-Zone to Recycle Waste Anesthetic Gases

Piramal Critical Care and Blue-Zone Technologies will collaborate on capturing and recycling waste anesthetic gases. The partnership will initially offer Blue-Zone's capture systems in France and Germany, with Piramal processing the gas to produce Sevoflurane USP in Canada. This initiative aims to reduce environmental impact and promote sustainable healthcare.

Piramal Pharma: Independent Director Subramanian Ramadorai Completes Tenure on Feb 8

Mr. Subramanian Ramadorai completes his 5-year term as Independent Director of Piramal Pharma Limited on February 8, 2026. He will retire from the Board and its committees effective February 9, 2026, to pursue personal priorities. The Board expressed gratitude for his service.

Piramal Pharma Limited's Dahej Plant Faces Closure Order from GPCB

Piramal Pharma Limited's Dahej plant faces a closure order from the Gujarat Pollution Control Board within 48 hours due to alleged water pollution violations. The company plans to challenge the order in the Gujarat High Court, deeming the violations unsubstantiated.

Piramal Pharma Ltd.: Transcript of Q3 FY26 Results Conference Call Released

Piramal Pharma Limited released the transcript of its conference call discussing the unaudited financial results for Q3 FY26 and the nine months ended December 31, 2025. The call took place on January 29, 2026, and the transcript is available on the company's website.

Piramal Pharma: Audio Recording of Q3 FY26 Results Conference Call Available

Piramal Pharma Limited released the audio recording of its conference call on January 29, 2026. The call focused on the unaudited financial results for the quarter and nine months ending December 31, 2025.

Piramal Pharma Designates Four Senior Management Personnel, Company Secretary Resigns

Piramal Pharma Limited has designated four new Senior Management Personnel: Rashida Najmi, Jatin Lal, Sandeep Rathod, and Puneet Rajput. Company Secretary Tanya Sanish resigned, effective February 20, 2026. Pratibha Mishra has been appointed as Interim Company Secretary and Compliance Officer, effective February 21, 2026.

Piramal Pharma Ltd.: Key management changes announced

Piramal Pharma Limited announced changes in its senior management. Ms. Rashida Najmi, Mr. Jatin Lal, Mr. Sandeep Rathod, and Ms. Puneet Rajput have been designated as Senior Management Personnel. Ms. Tanya Sanish resigned as Company Secretary and Compliance Officer, effective Feb 20, 2026. Ms. Pratibha Mishra appointed as Interim Company Secretary and Compliance Officer from Feb 21, 2026.

Piramal Pharma Q3 FY26 Results: Revenue Down 3%, PAT at (₹136) Crore

Piramal Pharma reported Q3 FY26 consolidated revenue of ₹2,140 crore (down 3% YoY) and a PAT loss of ₹136 crore. EBITDA fell 32% to ₹239 crore. The company noted signs of recovery in order inflows and is acquiring Kenalog® for up to US$100 million. A conference call is scheduled for January 29, 2026.

Piramal Pharma Appoints Pratibha Mishra as Interim Company Secretary

Piramal Pharma Limited designated four new Senior Management Personnel. Ms. Tanya Sanish resigned as Company Secretary and Compliance Officer, effective Feb 20, 2026. Ms. Pratibha Mishra appointed as Interim Company Secretary and Compliance Officer from Feb 21, 2026.

Piramal Pharma Q3FY26 Revenue Drops 3% to ₹2,140 Crore; PAT at (₹136) Crore

Piramal Pharma's Q3 FY26 revenue fell 3% YoY to ₹2,140 crore, with PAT at a loss of ₹136 crore. The CDMO segment declined 9% while PCH grew 20%. The company noted signs of recovery with increased RFPs and is acquiring Kenalog® for up to US$100 million.

Piramal Pharma Ltd Appoints 4 Senior Management Personnel, Welcomes New Company Secretary

Piramal Pharma Limited designated four new Senior Management Personnel, including Ms. Rashida Najmi (Chief Quality Officer) and Mr. Jatin Lal (President – M&A). Ms. Tanya Sanish resigned as Company Secretary and Compliance Officer, effective February 20, 2026. Ms. Pratibha Mishra will take over as Interim Company Secretary and Compliance Officer from February 21, 2026.

Piramal Pharma Acquires Kenalog® Brand from BMS for up to $100M

Piramal Pharma Limited's subsidiary will acquire the Kenalog® brand from BMS for an upfront payment of US$ 35 million and contingent consideration up to US$ 65 million. This acquisition aims to expand PPL's product portfolio and global distribution network.

Piramal Pharma Schedules Investor Meetings in Feb 2026

Piramal Pharma Limited will hold investor meetings from February 3rd to February 25th, 2026. Meetings will take place in Singapore, Hongkong, and Mumbai. Dates are subject to change.

Piramal Pharma Ltd: Shareholders Approve Appointment of Amit Soni as Independent Director

Piramal Pharma Limited shareholders approved the appointment of Mr. Amit Soni as Independent Director via postal ballot and e-voting. The resolution passed with 99.97% of valid votes in favor. The voting period concluded on January 16, 2026.

Piramal Pharma Schedules Q3 FY26 Earnings Conference Call for Jan 29

Piramal Pharma Limited will host a conference call on January 29, 2026, to discuss its Q3 and 9M FY2026 results. The call is scheduled from 9:30 AM to 10:15 AM IST, with various international dial-in options available.

Piramal Pharma Ltd. Submits Newspaper Advertisement for Postal Ballot Notice

Piramal Pharma Limited has published a newspaper advertisement regarding its Notice of Postal Ballot. The advertisement appeared in Business Standard (English) and Mumbai Lakshad weep (Marathi) on December 18, 2025. The company has also updated its website with this information.

Piramal Pharma Ltd. Seeks Approval for Amit Soni's Independent Director Appointment

Piramal Pharma Limited is seeking shareholder approval for the appointment of Mr. Amit Soni as an Independent Director for a five-year term from February 9, 2026, to February 8, 2031. Remote e-voting will be open from December 18, 2025, to January 16, 2026. Mr. Soni has significant experience in investment across various sectors.

Piramal Pharma Ltd. seeks member approval for Amit Soni's Independent Director appointment

Piramal Pharma Limited is seeking shareholder approval via postal ballot for the appointment of Mr. Amit Soni as an Independent Director for a five-year term from February 9, 2026, to February 8, 2031. Remote e-voting will be open from December 18, 2025, to January 16, 2026.

Piramal Pharma's Lexington Facility Receives 4 Observations from US FDA Inspection

Piramal Pharma's Lexington facility was inspected by the US FDA from December 3-10, 2025. The inspection resulted in a Form-483 with four observations related to procedural enhancements, classified as VAI. The company is preparing its response for submission within regulatory timelines.

Piramal Pharma appoints Amit Soni as Independent Director

Piramal Pharma appoints Amit Soni as an Independent Director for a five-year term starting February 9, 2026, pending shareholder approval. Soni is a Partner at CVC Capital.

Piramal Pharma Limited Intimates Schedule of Analyst/Institutional Investor Meetings

Piramal Pharma Limited announced the schedule of Analyst/ Institutional Investor Meetings with Citi India Pharma & Healthcare Tour 2025 scheduled on 28th November, 2025 in Mumbai.

Piramal Pharma releases conference call transcript for Q2 and H1 FY26 financial results

Piramal Pharma released the conference call transcript for Q2 and H1 FY26 unaudited financial results, which were for the quarter and half year ended 30th September 2025, held on 6th November 2025.

Piramal Pharma releases audio recording of Q2 FY26 results conference call

Piramal Pharma Limited has made the audio recording of its conference call, held on 6th November 2025, discussing Q2 FY26 results, available on its website.

Piramal Pharma Announces Q2 & H1 FY26 Results; Concall on Nov 6, 2025

Piramal Pharma announced Q2 & H1 FY26 results with revenue at ₹ 2,044 Cr & ₹ 3,977 Cr respectively. EBITDA margins at 11% & 10%. Concall on Nov 6, 2025.

Piramal Pharma announces Q2 & H1 FY26 results; Revenue and EBITDA decline YoY

Piramal Pharma reported a decline in Q2 & H1 FY26 consolidated revenue and EBITDA, with a net loss, primarily due to CDMO inventory destocking. Management notes improving biopharma funding and anticipates better future performance.

Piramal Pharma Announces Unaudited Financial Results for Quarter Ended Sep 30, 2025

Piramal Pharma Limited's Board approved the unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2025. Standalone PAT ₹196.33 crore. Consolidated Net loss ₹99.22 crore.

Piramal Pharma announces schedule of Analyst/Institutional Investor Meetings

Piramal Pharma Limited announced the schedule of Analyst/Institutional Investor Meetings to be held in Mumbai on November 11, 17, and 19, 2025.

Piramal Pharma Limited Announces Q2 & H1 FY26 Earnings Conference Call

Piramal Pharma Limited is hosting a conference call on November 6, 2025, to discuss the Q2 and H1 FY26 results. Dial-in details are provided for various regions.

ICRA Withdraws Piramal Pharma's ₹100 Crore Commercial Paper Credit Rating

ICRA has withdrawn Piramal Pharma's [ICRA]A1+ credit rating for its ₹100 crore Commercial Paper Programme at the company's request due to no open issues.

Piramal Pharma Amends Fair Disclosure Code for UPSI, aligning with SEBI PIT Regulations

Piramal Pharma to meet with DAM Capital on 23 Sep 2025

Piramal Pharma Reports Robust FY25 Financial Growth and Significant Sustainability Achievements

PPS and NewAmsterdam Pharma invest in oral solid dosage capabilities

Piramal Pharma's subsidiary completes subscription of PPL Pharma Inc shares

Piramal Pharma Limited Announces Schedule of Analyst/Institutional Investor Meetings

Piramal Pharma announces availability of Q1 FY26 earnings call transcript

Piramal Pharma's 5th AGM: Resolutions Passed, Dividend Declared

Piramal Pharma Board Approves Unaudited Financial Results for Quarter Ended June 30, 2025

Piramal Pharma Sells Decommissioned Thane Unit for Approximately ₹8.50 Crore